These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment]. Pushkar' DIu; Rasner PI; Skobelev PP Urologiia; 2001; (6):48-54. PubMed ID: 11785083 [No Abstract] [Full Text] [Related]
7. [Measurement of complexed prostatic specific antigen. A new challenge in PSA era]. Morote Robles J Med Clin (Barc); 2004 Feb; 122(7):256-8. PubMed ID: 15012874 [No Abstract] [Full Text] [Related]
8. The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Partin AW; Carter HB Urol Clin North Am; 1996 Nov; 23(4):531-40. PubMed ID: 8948408 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917 [TBL] [Abstract][Full Text] [Related]
10. Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. Lein M; Jung K; Brux B; Knäbich A; Sinha P; Schnorr D; Loening SA J Urol; 1999 Aug; 162(2):502-3. PubMed ID: 10411077 [No Abstract] [Full Text] [Related]
11. [Circulating prostatic-specific antigen in benign hypertrophy and localized prostate cancer: can PSA be considered a screening examination for localized cancer?]. Perrin P; Francois O; Maquet JH; Bringeon G; Duteil P; Devonec M Prog Urol; 1991 Jun; 1(3):419-31. PubMed ID: 1726943 [TBL] [Abstract][Full Text] [Related]
12. Prostate cancer and prostate specific antigen. A Jamaican perspective. Douglas LL West Indian Med J; 1999 Jun; 48(2):47-9. PubMed ID: 10492600 [No Abstract] [Full Text] [Related]
13. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA]. Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041 [TBL] [Abstract][Full Text] [Related]
14. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656 [TBL] [Abstract][Full Text] [Related]
15. [Usefulness of PSA density (PSAD) in the differential diagnosis between prostatic adenocarcinoma and benign ++ prostatic hypertrophy]. Tiranti D; Annoscia S; Montefiore F; Boccafoschi C Arch Ital Urol Androl; 1994 Sep; 66(4 Suppl):59-63. PubMed ID: 7534168 [TBL] [Abstract][Full Text] [Related]
16. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed]. Bratt O; Björk T Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615 [No Abstract] [Full Text] [Related]
17. Free PSA as a percentage of the total: where do we go from here? Moore RA Clin Chem; 1997 Sep; 43(9):1561-2. PubMed ID: 9299933 [No Abstract] [Full Text] [Related]
18. The PSA revisited: potentials and pitfalls. Harv Mens Health Watch; 1999 Jun; 3(11):1-5. PubMed ID: 10233802 [No Abstract] [Full Text] [Related]
19. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml. Akdas A; Tarcan T; Türkeri L; Cevik I; Biren T; Ilker Y Eur Urol; 1996; 29(2):189-92. PubMed ID: 8647145 [TBL] [Abstract][Full Text] [Related]